FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035896066> ?p ?o ?g. }

• W3035896066 endingPage "243" @default.
• W3035896066 startingPage "236" @default.
• W3035896066 abstract "The efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for EGFR-mutated non-adenocarcinoma (ADC) non-small cell lung cancer patients is not well established. Herein, we investigated key prognostic factors influencing the efficacy of EGFR-TKIs in these patients.A total of 12,320 lung cancer patients pathologically diagnosed in 2012 at teaching hospitals in Japan were retrospectively selected. The follow-up survey was closed in 2016.EGFR-mutated non-ADC patients were more prone to malignant pleural effusion (MPE) and distant metastasis than ADC patients (P = 0.071 and 0.022, respectively). EGFR-mutated ADC patients were likely to have a longer median overall survival (OS) than non-ADC patients [hazard ratio (HR) 1.3 (95 % CI, 0.97-1.8, P = 0.072)-29.5 months (95 % CI, 27.9-31.1 months) versus 19.5 months (95 % CI, 10.8-28.2 months) (P = 0.068)]. There was no significant difference in median OS between EGFR-positive ADC and non-ADC patients receiving treatment with first-generation EGFR-TKI. Among EGFR-positive non-ADC patients, the median OS was significantly longer for patients receiving EGFR-TKI treatment than for those who did not [HR 4.5 (95 % CI, 2.1-9.8, P < 0.001)-25.5 months (95 % CI, 8.1-42.9 months) versus 7.5 months (95 % CI, 3.4-11.6 months) (P < 0.001)]. While there was no significant difference in the median OS for ADC patients with either 19 del or L858R mutations, the median OS was significantly longer for EGFR-mutated non-ADC patients with 19 del than for those with L858R mutation (HR 3.2 [95 % CI, 1.5-6.9, P = 0.004]; it was not reached for 19 del and was 15.5 months for L858R [95 % CI, 6.6-24.4 months], P = 0.002).EGFR-mutated non-ADC patients were more prone to MPE and distant metastasis. Both ADC and EGFR del19-positive non-ADC patients can benefit from EGFR-TKI treatment, whereas EGFR L858R-positive non-ADC patients might require different therapeutic options." @default.
• W3035896066 created "2020-06-25" @default.
• W3035896066 creator A5006169496 @default.
• W3035896066 creator A5012338301 @default.
• W3035896066 creator A5016770292 @default.
• W3035896066 creator A5027580659 @default.
• W3035896066 creator A5030864419 @default.
• W3035896066 creator A5032337115 @default.
• W3035896066 creator A5035882975 @default.
• W3035896066 creator A5037355181 @default.
• W3035896066 creator A5037746646 @default.
• W3035896066 creator A5060063956 @default.
• W3035896066 creator A5066498071 @default.
• W3035896066 creator A5066700160 @default.
• W3035896066 creator A5072724155 @default.
• W3035896066 creator A5073381036 @default.
• W3035896066 creator A5077482201 @default.
• W3035896066 creator A5080980467 @default.
• W3035896066 date "2020-08-01" @default.
• W3035896066 modified "2023-10-02" @default.
• W3035896066 title "Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database" @default.
• W3035896066 cites W1561758716 @default.
• W3035896066 cites W1574226582 @default.
• W3035896066 cites W1981445628 @default.
• W3035896066 cites W1988552177 @default.
• W3035896066 cites W1998499306 @default.
• W3035896066 cites W2004426145 @default.
• W3035896066 cites W2006379423 @default.
• W3035896066 cites W2010065353 @default.
• W3035896066 cites W2012295597 @default.
• W3035896066 cites W2031121149 @default.
• W3035896066 cites W2038667141 @default.
• W3035896066 cites W2043696829 @default.
• W3035896066 cites W2056659899 @default.
• W3035896066 cites W2111662961 @default.
• W3035896066 cites W2115615857 @default.
• W3035896066 cites W2118322864 @default.
• W3035896066 cites W2120598067 @default.
• W3035896066 cites W2132157071 @default.
• W3035896066 cites W2132870547 @default.
• W3035896066 cites W2133149289 @default.
• W3035896066 cites W2134632205 @default.
• W3035896066 cites W2139248078 @default.
• W3035896066 cites W2145835533 @default.
• W3035896066 cites W2154662831 @default.
• W3035896066 cites W2158334356 @default.
• W3035896066 cites W2160982674 @default.
• W3035896066 cites W2161821474 @default.
• W3035896066 cites W2166084034 @default.
• W3035896066 cites W2251851976 @default.
• W3035896066 cites W2290479897 @default.
• W3035896066 cites W2497746146 @default.
• W3035896066 cites W2535300095 @default.
• W3035896066 cites W2626282040 @default.
• W3035896066 cites W2750974247 @default.
• W3035896066 cites W2760639821 @default.
• W3035896066 cites W2769659311 @default.
• W3035896066 cites W2770828094 @default.
• W3035896066 cites W2791290180 @default.
• W3035896066 cites W2924289105 @default.
• W3035896066 cites W2944860885 @default.
• W3035896066 cites W2978677918 @default.
• W3035896066 cites W2990041408 @default.
• W3035896066 doi "https://doi.org/10.1016/j.lungcan.2020.06.015" @default.
• W3035896066 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32590236" @default.
• W3035896066 hasPublicationYear "2020" @default.
• W3035896066 type Work @default.
• W3035896066 sameAs 3035896066 @default.
• W3035896066 citedByCount "7" @default.
• W3035896066 countsByYear W30358960662021 @default.
• W3035896066 countsByYear W30358960662022 @default.
• W3035896066 countsByYear W30358960662023 @default.
• W3035896066 crossrefType "journal-article" @default.
• W3035896066 hasAuthorship W3035896066A5006169496 @default.
• W3035896066 hasAuthorship W3035896066A5012338301 @default.
• W3035896066 hasAuthorship W3035896066A5016770292 @default.
• W3035896066 hasAuthorship W3035896066A5027580659 @default.
• W3035896066 hasAuthorship W3035896066A5030864419 @default.
• W3035896066 hasAuthorship W3035896066A5032337115 @default.
• W3035896066 hasAuthorship W3035896066A5035882975 @default.
• W3035896066 hasAuthorship W3035896066A5037355181 @default.
• W3035896066 hasAuthorship W3035896066A5037746646 @default.
• W3035896066 hasAuthorship W3035896066A5060063956 @default.
• W3035896066 hasAuthorship W3035896066A5066498071 @default.
• W3035896066 hasAuthorship W3035896066A5066700160 @default.
• W3035896066 hasAuthorship W3035896066A5072724155 @default.
• W3035896066 hasAuthorship W3035896066A5073381036 @default.
• W3035896066 hasAuthorship W3035896066A5077482201 @default.
• W3035896066 hasAuthorship W3035896066A5080980467 @default.
• W3035896066 hasBestOaLocation W30358960662 @default.
• W3035896066 hasConcept C121608353 @default.
• W3035896066 hasConcept C126322002 @default.
• W3035896066 hasConcept C143998085 @default.
• W3035896066 hasConcept C207103383 @default.
• W3035896066 hasConcept C2776232967 @default.
• W3035896066 hasConcept C2776256026 @default.
• W3035896066 hasConcept C2779438470 @default.
• W3035896066 hasConcept C2779634585 @default.

• next